跳转至内容
Merck
CN
  • Optical coherence tomography in ST-elevation myocardial infarction treated with novel drug-eluting stent: preprocedural, postimplant and 2-month follow-up findings.

Optical coherence tomography in ST-elevation myocardial infarction treated with novel drug-eluting stent: preprocedural, postimplant and 2-month follow-up findings.

Journal of cardiovascular medicine (Hagerstown, Md.) (2010-11-04)
Vasile Sirbu, Giuseppe Musumeci, Luigi Fiocca, Angelina Vassileva, Roberta Rossini, Nikoloz Lortkipanidze, Aleksandre Matiashvili, Laurian Mihalcsik, Antonello Gavazzi, Orazio Valsecchi, Giulio Guagliumi
摘要

The use of drug-eluting stents (DES) allowed the reduction in the need for repeat revascularization. At the culprit site in acute myocardial infarction patients treated with first-generation DES, the interaction between the eluted drug and the underlying necrotic core may generate different patterns of pathologic vessel response and delayed healing. A new generation DES intrepide elutes trapidil. Its modes of action are neither cytotoxic nor cytostatic, and may promote normal re-endothelialization. Due to its high resolution, optical coherence tomography (OCT) allows accurate detection of thrombus deposition and stent strut coverage at follow-up. Intravascular ultrasound (IVUS) has enhanced tissue penetration and provides information on vessel remodeling. Using OCT and IVUS, we evaluated the intravascular morphology of the culprit vessel, the acute and intermediate result of novel DES implanted to treat an ST-segment elevation myocardial infarction.

材料
产品编号
品牌
产品描述

曲匹地尔, European Pharmacopoeia (EP) Reference Standard